97 related articles for article (PubMed ID: 2844186)
1. Inhibition of calmodulin function by CV-159, a novel dihydropyridine compound.
Umekawa H; Yamakawa K; Nunoki K; Taira N; Tanaka T; Hidaka H
Biochem Pharmacol; 1988 Sep; 37(18):3377-81. PubMed ID: 2844186
[TBL] [Abstract][Full Text] [Related]
2. Interaction of the dihydropyridine calcium antagonist, CD-349, with calmodulin.
Tanaka M; Muramatsu M; Aihara H; Otomo S
Biochem Pharmacol; 1990 Sep; 40(5):991-6. PubMed ID: 2167684
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of a dihydropyridine derivative, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarbox ylic acid methyl 6-(5-phenyl-3-pyrazolyloxy)hexyl ester (CV-159), on rat ischemic brain injury.
Miyazaki H; Tanaka S; Fujii Y; Shimizu K; Nagashima K; Kamibayashi M; Uehara T; Okuma Y; Nomura Y
Life Sci; 1999; 64(10):869-78. PubMed ID: 10096437
[TBL] [Abstract][Full Text] [Related]
4. Calmodulin antagonistic action of KS-504a, a novel metabolite of the fungus Mollisia ventosa.
Nakanishi S; Kuroda K; Osawa K; Kase H
Agric Biol Chem; 1990 Oct; 54(10):2697-702. PubMed ID: 1369297
[TBL] [Abstract][Full Text] [Related]
5. Modulation of calmodulin function and of Ca2+-induced smooth muscle contraction by the calmodulin antagonist, HT-74.
Tanaka T; Umekawa H; Saitoh M; Ishikawa T; Shin T; Ito M; Itoh H; Kawamatsu Y; Sugihara H; Hidaka H
Mol Pharmacol; 1986 Mar; 29(3):264-9. PubMed ID: 3005834
[TBL] [Abstract][Full Text] [Related]
6. Different sensitivities of Ca2+, calmodulin-dependent cyclic nucleotide phosphodiesterases from rabbit aorta and brain to dihydropyridine calcium channel blockers.
Matsushima S; Tanaka T; Saitoh M; Watanabe M; Hidaka H
Biochem Biophys Res Commun; 1987 Nov; 148(3):1468-74. PubMed ID: 2825687
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of the drug-binding sites of calmodulin.
Zimmer M; Hofmann F
Eur J Biochem; 1987 Apr; 164(2):411-20. PubMed ID: 3032617
[TBL] [Abstract][Full Text] [Related]
8. Ca2+-dependent cyclic nucleotide phosphodiesterase is activated by poly(L-aspartic acid).
Tanaka T; Ito M; Ohmura T; Hidaka H
Biochemistry; 1985 Sep; 24(19):5281-4. PubMed ID: 3000429
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human platelet secretion and of Ca2+, calmodulin-dependent protein phosphorylation by the antiallergic agent GMCHA.
Tanaka T; Saitoh M; Ito M; Shin T; Naka M; Endo K; Hidaka H
Biochem Pharmacol; 1988 Jul; 37(13):2537-42. PubMed ID: 3390216
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of NZ-105, a 1,4-dihydropyridine derivative, on cyclic nucleotide phosphodiesterase activity.
Yamashita T; Masuda Y; Sakai T; Tanaka S; Kasuya Y
J Pharm Pharmacol; 1993 Jun; 45(6):530-4. PubMed ID: 7689649
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists.
Sharma RK; Wang JH; Wu Z
J Neurochem; 1997 Aug; 69(2):845-50. PubMed ID: 9231746
[TBL] [Abstract][Full Text] [Related]
12. Effects of ruthenium red on activation of Ca2(+)-dependent cyclic nucleotide phosphodiesterase.
Masuoka H; Ito M; Nakano T; Naka M; Tanaka T
Biochem Biophys Res Commun; 1990 May; 169(1):315-22. PubMed ID: 1693502
[TBL] [Abstract][Full Text] [Related]
13. Effects of the new dihydropyridine derivative 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 6-(5-phenyl-3-pyrazolyloxy)hexyl ester on the cardiohemodynamics and the energy metabolism of ischemic myocardium.
Imai H; Matsui K; Ochi S; Nakazawa M; Nakagawa Y; Imai S
Arzneimittelforschung; 1987 Dec; 37(12):1348-52. PubMed ID: 3449062
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of calmodulin-activated smooth-muscle myosin light-chain kinase by calmodulin-binding peptides and fluorescent (phosphodiesterase-activating) calmodulin derivatives.
Török K; Cowley DJ; Brandmeier BD; Howell S; Aitken A; Trentham DR
Biochemistry; 1998 Apr; 37(17):6188-98. PubMed ID: 9558358
[TBL] [Abstract][Full Text] [Related]
15. [Interaction of calcium agonists and antagonists with Ca-binding proteins and their effect on cyclic nucleotide phosphodiesterase].
Feoktistov IA; Baldenkov GN; Barannik IV; Cherviakov EB; Larionov NP
Biokhimiia; 1990 Apr; 55(4):754-9. PubMed ID: 2165822
[TBL] [Abstract][Full Text] [Related]
16. Calcium-dependent and -independent interactions of the calmodulin-binding domain of cyclic nucleotide phosphodiesterase with calmodulin.
Yuan T; Walsh MP; Sutherland C; Fabian H; Vogel HJ
Biochemistry; 1999 Feb; 38(5):1446-55. PubMed ID: 9931009
[TBL] [Abstract][Full Text] [Related]
17. The effect of K-252a, a potent microbial inhibitor of protein kinase, on activated cyclic nucleotide phosphodiesterase.
Matsuda Y; Nakanishi S; Nagasawa K; Iwahashi K; Kase H
Biochem J; 1988 Nov; 256(1):75-80. PubMed ID: 2851986
[TBL] [Abstract][Full Text] [Related]
18. Thyroid hormones inhibit the Ca2+ calmodulin-induced activation of myosin light chain kinase.
Hagiwara M; Mamiya S; Ochiai M; Hidaka H
Biochem Biophys Res Commun; 1988 Apr; 152(1):270-6. PubMed ID: 3358764
[TBL] [Abstract][Full Text] [Related]
19. Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes.
Walsh MP; Sutherland C; Scott-Woo GC
Biochem Pharmacol; 1988 Apr; 37(8):1569-80. PubMed ID: 2833901
[TBL] [Abstract][Full Text] [Related]
20. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle.
Hagiwara M; Endo T; Hidaka H
Biochem Pharmacol; 1984 Feb; 33(3):453-7. PubMed ID: 6322804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
